206 Users Online
Regenerative Therapies Market Segmented By Allograft, Xenograft, Alloplast Tissue Type in Soft Tissue Repair, Cardiovascular, Dental, Orthopedic, CNS disease treatment,
Worldwide revenue from the regenerative therapies market stands at US$ 9.75 Bn in 2022, with the global market estimated to expand at a CAGR of 8.7% to reach US$ 24.41 Bn by the end of 2033.
As assessed by Persistence Market Research, Regenerative Therapies for Oncology accounted for a market value of US$ 2.67 Bn in 2022. Overall, regenerative therapies revenue accounted for approximately 84.8% revenue share of the global biomedical and tissue engineering market in 2022 valued at around US$ 11.5 Bn.
The global market for regenerative therapies recorded a historic CAGR of 8.4% in the last 6 years from 2017 to 2022.
Finding the ideal patient and therapy regimen to fit is a constant problem in cancer practice. The odds of success are sometimes slim, making this undertaking intimidating. As a result, improved therapies and the capacity to apply findings from basic science to the clinical environment depend on a new knowledge of the biology of cancer.
Stem cells are the frontiers of regenerative medicine due to their unending capacity for self-renewal and ability to differentiate into numerous cell types.
Regenerative Therapies Market Size (2022)
US$ 9.75 Bn
Projected Market Value (2033)
US$ 24.41 Bn
Global Market Growth Rate (2023-2033)
Market Share of Top 5 Countries
“Deficiency in Therapeutic Requirements is Expected to Fuel the Market”
The newest and fastest-growing field of medicine, regenerative medicine, focuses on the functional repair of tissues or organs for patients with catastrophic injuries or persistent illnesses. The extraordinary advancements in stem cell research have paved the way for driving cell-based therapeutics for illnesses that are resistant to traditional medicine.
The ability of stem cells to transdifferentiate differs depending on the source, and regenerative applications shift as a result. The patient-derived re-modelling of stem cells grown into 3D organoids and tissue architectures for individualized applications has been supported by advances in gene editing and tissue engineering technologies.
The deficiency of therapeutic requirements is the main growth engine for the global regenerative therapies market. There have been many factors adding to the current increase in government support for the treatment of various diseases on a global scale. This includes sizable investments in regenerative therapies for the establishment of centres of excellence, policy initiatives and supportive legislative’s creation and implementation, growing research networks, manufacturing infrastructure, as well as commercialization centres, among other things.
Other significant factors propelling the growth of the global regenerative therapies market at the moment include the growing demands for tissue-cell and stem-cell research technologies along with the products created from them, which are used to treat a variety of chronic diseases with no permanent cure.
“Decrease in the Meeting of Demands for Organ Transplantation by Donation”
The need for transplantation of ageing and ill populations, which has pushed the quest for alternatives, cannot currently be met by donated tissues and organs. Regenerative therapies, including tissue engineering, gene therapy, and stem cell research, open the door for potential advantages in these urgent situations. Stem cells have recently become a leading source in regenerative medicine for the repair of tissues and organ anomalies caused by congenital defects, disease, and age-related effects. Stem cells are affirmed with indefinite cell division potential and can transdifferentiate into the other types of cells.
“Lack of Financial-Backing of Smaller Firms”
A common trait in the regenerative therapies industry is the unavailability of proper financing options for smaller organizations. This is one of the main factors hampering R&D in the field of advanced research in regenerative therapies.
Quite observed in resource-poor settings, many promising targets have been abandoned halfway during clinical trial phase due to a lack of financing support stemming from insufficient data on proven efficacy.
Furthermore, the emergence and growth of start-ups researching on and producing regenerative therapies have been hampered by a lack of lucrative co-marketing collaborations from medical devices companies (especially in orthopaedics – the largest application segment in terms of revenue generation) and in-licensing and out-licensing deals.
There exists a significant amount of skepticism among physicians and clinicians working with regenerative therapies. Quite frequently, it has been observed that patients’ long-term safety, tolerability, and treatment efficacy are at stake after the usage of approved regenerative therapies.
Why is the U.S. Regenerative Therapies Market Booming?
“Increasing Number of Cancer Related Deaths to Improve the Required Therapies”
The U.S. accounted for 24.2% share of the global market in 2022, and a similar trend is expected over the forecast period.
According to U.S. Department of Health & Human Services, Cancer is the second leading cause of death in the United States, exceeded only by heart disease. One of every five deaths in the United States is due to cancer.
This high number of oncology and its related treatments require the use of rehabilitation for the affected population. The National Institute of Standards and Technology is devoted to resolving the issues of advances in manufacturing technologies and measurements in this quickly developing area of the economy by offering supporting measurement infrastructure, platform technologies, and standards in addition to support for manufacturing innovation, improved supply chain resilience, and support for characterization and testing to speed up regulatory approval.
In accordance with Section 3036 of the 21st Century Cures Act, the NIST Regenerative Medicine programme is collaborating closely with the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (FDA/CBER), the Standards Coordinating Body, and other larger industry. This is to develop international manufacturing and measurement standards supported by a strong measurement infrastructure required to advance product development and translation.
Why is Australia Emerging as a Prominent Market for Regenerative Therapies?
“Well Developed Technologies for Research and Development”
Australia held the second largest market share of 12.9% of the global regenerative therapies market in 2022, with a market value of US$ 1.25 Bn.
Australia has a solid foundation on which to flourish. There is no need to start from scratch. Its strengths include a depth of talent in basic research and clinical trials, a patient population with a wide range of ethnicities interested in advancing medical technology, and financial incentives. This makes Australia an appealing location for conducting health and medical research, such as the R&D tax incentive, a high quality, and quick clinical trial system, and focused world-class manufacturing & cell processing technologies, such as Cell Therapies Pty Ltd, Royal Pharm, etc.
Will India be a Lucrative Market for Regenerative Therapies?
“Government Support and Funding have Supported the Market to Establish”
India held 7.8% share of the global market in 2022.
Regenerative medicine research and development, along with indigenous innovation and commercial development activities, have all received strong support from the Indian government. These factors add up to a revolution in Indian healthcare and public empowerment. For the development of inventive capability, a number of national and transnational linkages have formed, most notably in stem cell and cord blood banking, gene therapy, tissue engineering, biomaterials, and 3D printing.
A separate research organisation on this topic, the Institute for Stem Cell Biology and Regenerative Medicine (inStem), was also founded in 2009. (a DBT initiative). On a national and international level, this institute promotes networking, cooperative research, and therapeutic translation among academics, healthcare providers, and businesses.
What is the Outlook for the Regenerative Therapies Market in Japan?
“Healthcare Reforms in Japan fuels the Japanese Market in Regenerative Therapies”
Japan held 6.1% share of the global market in 2022.
Japanese government has been promoting liberalization of rules on regulations, which could expedite the route to market timeline for regenerative therapies.
Japan's healthcare reforms are moving forward to improve the system's accountability and support for providing the country's population with affordable, effective, and equitable medical treatment. Regenerative medicine began its journey in Japan's healthcare system in 2014. Regenerative medical goods, medicines, and medical devices were defined by reforms and modifications to two of the most important pharmaceutical statutes, the Pharmaceuticals and Medical Devices Act and the Act on the Safety of Regenerative Medicine. Regenerative therapies have the ability to completely heal chronic diseases in addition to lengthening life expectancy.
Which Therapy is Driving Global Market Growth?
“Rising Adoption of Tissue Engineering in the Regenerative Medicine”
Tissue engineering held 43.1% share of the overall therapy segment within the global market in 2022.
Tissue engineering (TE) has expanded significantly both as a science and as an enterprise over the past 25 years. The development of TE research is entwined with advancement in other domains through the analysis of cell function and behaviour in isolated biomimetic microenvironments, despite its traditional focus on recapitulating tissue and organ production in our body for regenerative medicine.
As a result, TE applications now go beyond the realm of tissue regeneration research. They serve as a platform for adaptable, physiologically accurate in vitro models that have the potential to enhance the translation of novel therapeutics into the clinic through a better understanding of the pertinent molecular biology, structural biology, anatomy, and physiology.
This makes the tissue engineering segment the maximum revenue-generating segment among the others.
Which Application is in High Demand?
“Rising Deaths Due to Cancer Drives the Market for an Alternative Treatment Regimen”
The oncology segment held the largest market share of 29.6% in 2022.
One of the major causes of death in the world is cancer, and finding new ways to anticipate, identify, and stop tumour cell proliferation is one of the biggest challenges in treating it. Although there are many ways to treat cancer today, including surgery, chemotherapy, and radiation therapy, its mortality rate is still high due to the multiple drawbacks of each strategy.
The discipline of regenerative medicine, which includes tissue engineering, cell therapy, and gene therapy, participates in the treatment of cancer and the creation of cancer models in order to better understand the biology of cancer.
Key players in the regenerative therapies industry are engaged in activities such as new product launches, acquisitions, collaborations, and expansion for the advancement and development of new products and therapies.
Historical Data Available for
USD Million for Value
Key Countries Covered
Key Market Segments Covered
Key Companies Profiled
Customization & Pricing
Available upon Request
By Therapy Types:
The global regenerative therapies market was valued at around US$ 9.75 Bn in 2022.
Sales of regenerative therapies are set to exhibit a growth rate of 8.7% and reach US$ 24.41 Bn by 2033.
Demand for regenerative therapies increased at 8.4% CAGR from 2017 to 2022.
The U.S., Australia, India, Japan, and U.K. accounted for the most demand for regenerative therapies and held a cumulative market share of 55.9% in 2022.
The U.S. will account for a 24.2% share of the global market by 2023.
AstraZeneca, Novartis AG, and Glaxo SmithKline Ltd. are the top three manufacturers of regenerative therapies medications.
Australia will hold a revenue share of 12.9% in the global market in 2023.
The South Asian regenerative therapies market is set to expand at a CAGR rate of close to 14.0% over the forecast period.
Japan will account for 6.1% share in the global market in 2023.
The European market is expected to grow at a CAGR 18.2% during the forecast period.